Literature DB >> 9291164

Growth factors and myelin regeneration in multiple sclerosis.

H D Webster1.   

Abstract

Insulin-like growth factor-I (IGF-I), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and ciliary neurotrophic factor (CNTF) are multifunctional growth factors which are found in the CNS. Oligodendroglia are the cells that form and maintain myelin sheaths and many in vitro experiments have shown that these growth factors promote the proliferation, differentiation and survival of cells in the oligodendroglial lineage. Since myelin breakdown is often severe in multiple sclerosis (MS), the possibility of growth factor use in the treatment of MS has been considered and recently, IGF-I treatment has been shown to reduce lesion severity and promote myelin regeneration in experimental autoimmune encephalomyelitis (EAE), an animal model of MS. This review briefly summarizes the structural characteristics of these growth factors and the actions which might help reduce oligodendrocyte-myelin sheath injury in MS and promote myelin regeneration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9291164     DOI: 10.1177/135245859700300210

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions.

Authors:  L A Boven; L Montagne; H S Nottet; C J De Groot
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

3.  Growth factors and synaptic plasticity in relapsing-remitting multiple sclerosis.

Authors:  Francesco Mori; Carolina G Nicoletti; Silvia Rossi; Caterina Motta; Hajime Kusayanagi; Alessandra Bergami; Valeria Studer; Fabio Buttari; Francesca Barbieri; Sagit Weiss; Robert Nisticò; Gianvito Martino; Roberto Furlan; Diego Centonze
Journal:  Neuromolecular Med       Date:  2014-03-27       Impact factor: 3.843

Review 4.  Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.

Authors:  Giuseppe Scalabrino
Journal:  Biomedicines       Date:  2022-03-30

5.  Investigation of Neuregulin-1 and Glial Cell-Derived Neurotrophic Factor in Rodent Astrocytes and Microglia.

Authors:  Jessica Kronenberg; Lukas Merkel; Sandra Heckers; Viktoria Gudi; Markus H Schwab; Martin Stangel
Journal:  J Mol Neurosci       Date:  2019-01-25       Impact factor: 3.444

6.  Neonatal and adult O4(+) oligodendrocyte lineage cells display different growth factor responses and different gene expression patterns.

Authors:  Grace Lin; Angeliki Mela; Eileen M Guilfoyle; James E Goldman
Journal:  J Neurosci Res       Date:  2009-11-15       Impact factor: 4.164

7.  Recognition of the kind of stress coping in patients of multiple sclerosis.

Authors:  A Hajhashemi; H D Vaziripour; H Baratian; M B Kajbaf; M Etemadifar
Journal:  Indian J Psychol Med       Date:  2010-07

8.  Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system.

Authors:  P Villoslada; S L Hauser; I Bartke; J Unger; N Heald; D Rosenberg; S W Cheung; W C Mobley; S Fisher; C P Genain
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

9.  Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.

Authors:  Matthew F Cusick; Jane E Libbey; Nikolaus S Trede; Robert S Fujinami
Journal:  PLoS One       Date:  2014-04-09       Impact factor: 3.240

Review 10.  Is multiple sclerosis a mitochondrial disease?

Authors:  Peizhong Mao; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.